Mirati Therapeutics, Inc.

Looking ahead to 2025, industry leaders shared their insights into the key trends and topics they expect to see. Click on topic headings to read executive predictions. The insights in this article hav

A recent promotion violation letter for Dexcel Pharma ’s Hemady shows how the US Food and Drug Administration is closely scrutinizing the design and results of studies purporting to support benefit c

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

Bristol Myers Squibb Company ’s Mirati Therapeutics, Inc. landed a US Food and Drug Administration untitled letter for the health care provider website of its lung cancer drug Krazati (adagrasib) du